Published in Semin Immunol on November 23, 2013
Study to Prevent Cartilage Damage Following Acute Knee Injury. | NCT00332254
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med (2015) 4.20
An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med (2014) 1.86
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm (2014) 1.07
Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol (2015) 1.02
Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun (2015) 0.94
International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease. Pharmacol Rev (2015) 0.92
Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr (2014) 0.91
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm (2015) 0.89
Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res (2015) 0.89
Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol (2014) 0.85
New Insights Into Tissue Macrophages: From Their Origin to the Development of Memory. Immune Netw (2015) 0.85
GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. J Exp Med (2016) 0.85
The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway. Arthritis Res Ther (2015) 0.84
Evasion of inflammasome activation by microbial pathogens. J Clin Invest (2015) 0.84
The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener (2016) 0.82
The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers. Biomaterials (2014) 0.81
Questions and controversies in innate immune research: what is the physiological role of NLRP3? Cell Death Discov (2016) 0.81
Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol (2014) 0.81
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest (2017) 0.81
Basic Characteristics of Adults with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenopathy Syndrome in Comparison with the Typical Pediatric Expression of Disease. Mediators Inflamm (2015) 0.80
Therapeutic Administration of a Monoclonal Anti-Il-1β Antibody Protects Against Experimental Melioidosis. Shock (2016) 0.80
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics (2016) 0.80
Gene therapy with the caspase activation and recruitment domain reduces the ocular inflammatory response. Mol Ther (2015) 0.80
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf (2015) 0.79
Role of IL-38 and its related cytokines in inflammation. Mediators Inflamm (2015) 0.79
Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications. Heart Fail Rev (2014) 0.79
Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World J Hepatol (2014) 0.79
Abrogating ClC-3 Inhibits LPS-induced Inflammation via Blocking the TLR4/NF-κB Pathway. Sci Rep (2016) 0.78
Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method. PLoS One (2015) 0.78
Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory State. Antimicrob Agents Chemother (2016) 0.78
Generation and Characterization of Mice Expressing a Conditional Allele of the Interleukin-1 Receptor Type 1. PLoS One (2016) 0.78
Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans. Nutr Diabetes (2015) 0.78
Suppression of NLRP3 inflammasome by γ-tocotrienol ameliorates type 2 diabetes. J Lipid Res (2015) 0.78
Tyrosine kinases: the molecular switch for inflammasome activation. Cell Mol Immunol (2014) 0.77
Old and new treatment targets in axial spondyloarthritis. RMD Open (2015) 0.77
Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc Res (2014) 0.77
Crosstalk between the heart and peripheral organs in heart failure. Exp Mol Med (2016) 0.77
The complex cascade of cellular events governing inflammasome activation and IL-1β processing in response to inhaled particles. Part Fibre Toxicol (2016) 0.77
Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial. Trials (2015) 0.77
Differential ASC requirements reveal a key role for neutrophils and a noncanonical IL-1β response to Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol (2015) 0.77
Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors? Stem Cells Int (2016) 0.76
The role of caloric load and mitochondrial homeostasis in the regulation of the NLRP3 inflammasome. Cell Mol Life Sci (2016) 0.76
Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6. Arthritis Rheumatol (2016) 0.76
The meteorology of cytokine storms, and the clinical usefulness of this knowledge. Semin Immunopathol (2017) 0.76
Genes Involved in Interleukin-1 Receptor Type II Activities Are Associated With Asthmatic Phenotypes. Allergy Asthma Immunol Res (2016) 0.75
LncRNA: a versatile regulator of the NF-κB signaling circuit. Immunology (2016) 0.75
Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain. PLoS One (2016) 0.75
Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances. F1000Res (2016) 0.75
Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis. Front Immunol (2017) 0.75
Gout increases risk of fracture: A nationwide population-based cohort study. Medicine (Baltimore) (2016) 0.75
A new treatment for knee osteoarthritis: Clinical evidence for the efficacy of Arthrokinex™ autologous conditioned serum. J Orthop (2016) 0.75
IL-1 receptor antagonist in sepsis: new findings with old data? J Thorac Dis (2016) 0.75
Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report. J Med Case Rep (2015) 0.75
Interleukin-1 as a mediator of fatigue in disease: a narrative review. J Neuroinflammation (2017) 0.75
NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils. Front Immunol (2017) 0.75
Differences of IL-1β Receptors Expression by Immunocompetent Cells Subsets in Rheumatoid Arthritis. Mediators Inflamm (2015) 0.75
Inflammasomes in Myeloid Cells: Warriors Within. Microbiol Spectr (2017) 0.75
Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients. Sci Rep (2016) 0.75
IL-1α mediates cellular cross-talk in the airway epithelial mesenchymal trophic unit. Tissue Barriers (2016) 0.75
C5a Regulates IL-1β Production and Leukocyte Recruitment in a Murine Model of Monosodium Urate Crystal-Induced Peritonitis. Front Pharmacol (2017) 0.75
IL-1 Receptor Signaling on Graft Parenchymal Cells Regulates Memory and De Novo Donor-Reactive CD8 T Cell Responses to Cardiac Allografts. J Immunol (2016) 0.75
Propiece IL-1α facilitates the growth of acute T-lymphocytic leukemia cells through the activation of NF-κB and SP1. Oncotarget (2017) 0.75
The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. Front Med (Lausanne) (2017) 0.75
Structural basis for IL-1α recognition by a modified DNA aptamer that specifically inhibits IL-1α signaling. Nat Commun (2017) 0.75
Salmonella typhimurium-induced IL-1 release from primary human monocytes requires NLRP3 and can occur in the absence of pyroptosis. Sci Rep (2017) 0.75
Differential role of pannexin-1/ATP/P2X7 axis in IL-1β release by human monocytes. FASEB J (2017) 0.75
A Brief History of IL-1 and IL-1 Ra in Rheumatology. Front Pharmacol (2017) 0.75
Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts. Infection (2017) 0.75
Different Regulation of Interleukin-1 Production and Activity in Monocytes and Macrophages: Innate Memory as an Endogenous Mechanism of IL-1 Inhibition. Front Pharmacol (2017) 0.75
A link between osteomyelitis and IL1RN and IL1B polymorphisms-a study in patients from Northeast Brazil. Acta Orthop (2017) 0.75
A comparison of Illumina and Ion Torrent sequencing platforms in the context of differential gene expression. BMC Genomics (2017) 0.75
Biologic basis for interleukin-1 in disease. Blood (1996) 16.04
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 11.62
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Type 2 diabetes as an inflammatory disease. Nat Rev Immunol (2011) 8.30
Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 7.25
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum (2004) 7.07
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest (2002) 5.52
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 5.01
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med (2005) 4.79
A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther (2007) 4.65
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet (2004) 4.23
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J (2011) 3.93
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum (2007) 3.65
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med (2009) 3.56
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Anti-inflammatory Agents: Present and Future. Cell (2010) 3.13
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab (2010) 3.11
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun (2001) 2.94
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 2.77
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis (2007) 2.75
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A (2006) 2.59
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care (2009) 2.56
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry (2005) 2.41
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A (2003) 2.30
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis (2009) 2.29
IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol (2011) 2.25
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation (2008) 2.23
Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum (2009) 2.23
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci (2001) 2.20
Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum (2005) 2.13
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2008) 2.08
Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A (2010) 2.04
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2009) 2.03
Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol (2010) 2.02
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum (2010) 2.00
Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A (2001) 1.97
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 1.95
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis (2012) 1.95
Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol (2009) 1.82
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun (2012) 1.80
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum (2011) 1.79
The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol (2009) 1.78
Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) (2012) 1.78
Topological frustration and the folding of interleukin-1 beta. J Mol Biol (2005) 1.77
Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum (2010) 1.75
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74
Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74
Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clin Pharmacol Ther (2012) 1.72
Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation (2012) 1.70
Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.69
TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol (2000) 1.68
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 1.64
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis (2005) 1.64
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine (1992) 1.63
Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A (2010) 1.60
NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum (2007) 1.60
Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol (2013) 1.56
Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol (2005) 1.55
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum (2005) 1.55
Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol (2011) 1.55
Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum (2009) 1.54
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis (2004) 1.53
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum (2010) 1.52
Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol (2011) 1.51
Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J Immunol (2009) 1.50
Neutrophilic urticaria with systemic inflammation: a case series. JAMA Dermatol (2013) 1.50
Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med (2005) 1.48
Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) (2005) 1.48
Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol (2009) 1.46
Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care (2012) 1.46
A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum (2008) 1.46
Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis. Pediatr Cardiol (2012) 1.44
Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory? Dermatology (2011) 1.43
Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α. Proc Natl Acad Sci U S A (2011) 1.41